1. Home
  2. Programs
  3. Medical Industry Feature
advertisement

Managing Occasional Constipation: The Role of PEG 3350

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

Hear expert insights on PEG 3350 as a recommended first-line agent for managing occasional constipation and how it compares to other treatments.

  • Sponsored by

  • Overview

    A recent consensus document determined that PEG 3350, the active ingredient in MiraLAX®, should be considered a first-line agent for managing occasional constipation.1 It's the most widely tested over-the-counter treatments specifically indicated for this condition.1 Learn more about MiraLAX® and how it compares to fiber laxatives, stool softeners, and stimulant laxatives with Dr. Darren Brenner. Dr. Brenner is a Professor of Medicine and Surgery and Director of the Northwestern Neurogastromotility Program in the Northwestern University Feinberg School of Medicine.

    Reference:

    1. Brenner DM, Corsetti M, Drossman D, Tack J, Wald A. Perceptions, definitions, and therapeutic interventions for occasional constipation: a Rome Working Group consensus document. Clin Gastroenterol Hepatol. 2024;22:397–412.

    Bayer, the Bayer Cross, MiraLAX, and Mix-In Pax are registered trademarks of Bayer.
    © 2025 Bayer April 2025 CH-20250404-82 

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free